How to Get GLP-1 Approved for Weight Loss in 2026

When people search how to get GLP-1 approved for weight loss, they're usually collapsing three completely different decisions into one word. This is the single biggest source of confusion — and the reason so many people get stuck, get denied, or give up before they even start.

For FDA-approved weight-loss medications in this class, adults generally need a BMI of 30 or higher, or a BMI of 27 or higher with at least one weight-related health condition. You do not need a diabetes diagnosis. Final candidacy depends on your full medical history, side-effect risk profile, and a clinician's evaluation.

BMI is an imperfect screening tool. It doesn't measure body composition, muscle mass, or metabolic health. But it's the metric every provider and insurer uses as a starting point, so you need to know your number. Use our BMI eligibility calculator to check.

These medications are not safe for everyone. You should not take them if you have a personal or family history of medullary thyroid carcinoma (MTC) or multiple endocrine neoplasia syndrome type 2 (MEN2), if you are pregnant or planning to become pregnant soon, or if you've had a severe allergic reaction to a GLP-1 medication in the past.

History of pancreatitis, eating disorders, and certain gallbladder conditions require careful evaluation with your clinician — they aren't always absolute disqualifiers, but they change the risk conversation. See our full GLP-1 contraindications guide for the complete breakdown.

Approval moves faster when you show up prepared. Across insurer prior-authorization requirements, manufacturer PA resources, and clinician intake forms, the same documentation keeps coming up. We assembled this into a single checklist — because right now, getting all of this in one place requires opening five different tabs.

Before you go through the clinical process, one phone call to the number on the back of your insurance card can save weeks of wasted effort. Ask these questions — in this order:

Prior authorization (PA) is the process where your insurance plan reviews your prescription before agreeing to cover it. For GLP-1 weight-management medications, PA is required by the vast majority of plans that offer any coverage at all.

The five most common PA criteria across major commercial insurers, based on manufacturer PA reference guides (e.g., Novo Nordisk's Wegovy PA Quick Reference Guide) and insurer documentation:

That means for the majority of employer plans, weight-loss GLP-1 coverage either doesn't exist or comes with significant hurdles. If your plan excludes obesity drugs, skip ahead to what to do when your plan excludes weight-loss drugs. For a complete walkthrough of the PA process — including appeal strategies and letter of medical necessity guidance — see our GLP-1 prior authorization guide.

A fast approval can happen in days. Incomplete submissions, manual reviews, and plan-specific bottlenecks can stretch timelines to weeks. Here's the realistic timeline across pathways.

CMS requires certain impacted payers to send standard PA decisions within 7 calendar days and urgent decisions within 72 hours. (Source: CMS Interoperability and Prior Authorization Final Rule, CMS-0057-F.) Real-world processing depends on documentation completeness.

This is the fork most GLP-1 approval guides bury — and it's the one that matters most for the majority of readers. If your employer plan or insurance specifically excludes "weight-loss medications" or "anti-obesity medications," prior authorization will not override that exclusion. A perfect PA submission hitting a plan exclusion is like a perfect key in the wrong lock.

Call the number on your insurance card and ask: "Does my plan have a blanket exclusion for anti-obesity medications or weight-loss drugs?" If they say yes, ask for the exact exclusion language in writing. Some "exclusions" have carve-outs — your employer may offer a separate weight-management program with different rules, or coverage may exist for a secondary indication (cardiovascular risk reduction, sleep apnea).

Appeals can work when the denial is due to a documentation gap — wrong diagnosis code, missing lab values, incomplete weight history. But appeals almost never work against a true plan exclusion. If the plan design says "no weight-loss drugs," better documentation won't change the plan design.

If your denial letter cites specific missing criteria rather than a blanket exclusion, work with your clinician to fix the gaps and resubmit. Ask your clinician to request a peer-to-peer review with the insurance company's medical reviewer — this takes the decision out of an administrative checkbox and puts it in front of a physician who can evaluate clinical nuance.

The fastest safe path depends on your situation. Here's the honest comparison — not just who's cheapest, but who's actually best for the approval gate you're stuck at.

If you have a doctor you trust who's comfortable prescribing weight-management medications, and you want insurance coverage, this is the most straightforward clinical path. Bring your approval packet and ask directly: "I'd like to discuss GLP-1 medication for weight management. Based on my BMI and health history, do I qualify?"

Not every PCP is experienced with these prescriptions. If your doctor says no for reasons that don't feel clinical, you're entitled to a second opinion.

This path makes the most sense if you've been denied by insurance before, have a complex medical history, or need the strongest possible documentation for an appeal. Obesity medicine specialists file prior authorizations as a core part of their practice. The tradeoff is longer wait times. Find a board-certified specialist through the American Board of Obesity Medicine directory.

Telehealth is faster, but "faster" means different things depending on whether you're using insurance or paying cash.

If your plan excludes obesity drugs, you've confirmed there's no covered indication that applies, and brand-name cash pricing is still out of reach — a clinician-managed compounded program can make treatment more accessible. But you need to go in with clear eyes.

Compounded GLP-1 medications are not FDA-approved as finished products. They have not undergone the same FDA review for safety, effectiveness, or quality as brand-name drugs. The FDA has cautioned consumers about misleading marketing — in March 2026, the agency issued warning letters to more than 30 telehealth companies for violations related to compounded GLP-1 marketing. (Source: FDA press announcement, March 2026.)

The FDA's BeSafeRx program warns that many unsafe online pharmacies sell prescription drugs without requiring a valid prescription — which is illegal. Beyond that, watch for:

• No medical evaluation required before prescribing
• No verifiable U.S. physical address or state pharmacy license
• No named compounding pharmacy (the pharmacy should be identifiable and verifiable)
• Claims that compounded products are "FDA-approved" or equivalent to brand-name drugs — they are not
• Pricing dramatically below market rates ($100/month or less for injectable GLP-1s) without explanation
• No pharmacist or provider accessible for questions

A denial is not the end. But the right next move depends on the reason — and most people don't bother to find out why before they give up or resubmit blindly. Don't do that.

Peer-to-peer review is often the most effective escalation for documentation-based denials. Ask your clinician to request a direct conversation with the insurance company's medical reviewer — this puts the decision in front of a physician who can evaluate clinical nuance rather than leaving it with an administrator checking boxes.

For the complete PA process, appeal strategies, and letter of medical necessity guidance, see our full prior authorization guide.

Public-program readers need a separate answer because the rules are changing faster than almost any other part of the GLP-1 landscape.

As of January 2026, only 13 state Medicaid fee-for-service programs cover GLP-1s for obesity treatment, according to KFF. That number decreased from 16 states after October 2025, when California, New Hampshire, Pennsylvania, and South Carolina dropped coverage (North Carolina later reinstated). (Source: KFF, "Medicaid Coverage of and Spending on GLP-1s.")

The BALANCE Model may expand Medicaid coverage starting May 2026 for states that opt to participate, but participation is voluntary. Not all states will opt in. When covered, Medicaid GLP-1 access is typically subject to prior authorization with strict criteria. See our Medicaid GLP-1 coverage guide for state-specific details.

We've covered the gates, the pathways, and the pitfalls. Here's the routing decision, simplified.